Flecainide: Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia

Edward V. Platia, N. A Mark Estes, Donald L. Heine, Lawrence S C Griffith, Hasan Garan, Jeremy N. Ruskin, Philip R. Reid

Research output: Contribution to journalArticle

Abstract

Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 ± 87 mg [mean ±standard deviation]). An average of 4 antiarrhythmic agents were used and were unsuccessful before therapy with flecainide was begun. During 64 ± 16 hours of control Holter monitoring in 16 patients, all had 1 or more salvos of VT, as well as ventricular premature complexes (VPCs). Programmed stimulation during the control period induced VT in 17 of 22 patients. After flecainide therapy, Holter monitoring showed elimination of all forms of VT in all but 1 patient, as well as significant reduction of paired VPCs by 95% (p <0.03) and single VPCs by 70% (p <0.005). Electrophysiologic study during flecainide therapy showed significant increases in AH, HV, PR, QRS and QTc intervals, and the ventricular effective refractory period. Programmed stimulation in 17 patients taking flecainide, with a mean plasma level of 1,075 ± 521 ng/ml, showed ablation of inducible VT in only 2 patients, a worsening in 5 and continued VT inducibility in 10. Adverse effects that required drug withdrawal were infrequent and encountered in patients who received higher drug levels: 1 patient with congestive heart failure and 1 with severe sinus bradycardia. Thus, although flecainide suppresses complex ventricular arrhythmias on Holter recordings, it rarely alters the response to programmed stimulation. Caution is recommended in its use for recurrent sustained VT or VF and in the interpretation of electrophysiologic studies until the predictive value of programmed stimulation with flecainide therapy is established.

Original languageEnglish (US)
Pages (from-to)956-962
Number of pages7
JournalThe American Journal of Cardiology
Volume55
Issue number8
DOIs
StatePublished - Apr 1 1985

Fingerprint

Flecainide
Ventricular Tachycardia
Ventricular Premature Complexes
Ambulatory Electrocardiography
Ventricular Fibrillation
Therapeutics
Ambulatory Monitoring
Bradycardia
Pharmaceutical Preparations
Cardiac Arrhythmias
Coronary Artery Disease
Heart Failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Platia, E. V., Estes, N. A. M., Heine, D. L., Griffith, L. S. C., Garan, H., Ruskin, J. N., & Reid, P. R. (1985). Flecainide: Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. The American Journal of Cardiology, 55(8), 956-962. https://doi.org/10.1016/0002-9149(85)90726-X

Flecainide : Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. / Platia, Edward V.; Estes, N. A Mark; Heine, Donald L.; Griffith, Lawrence S C; Garan, Hasan; Ruskin, Jeremy N.; Reid, Philip R.

In: The American Journal of Cardiology, Vol. 55, No. 8, 01.04.1985, p. 956-962.

Research output: Contribution to journalArticle

Platia, EV, Estes, NAM, Heine, DL, Griffith, LSC, Garan, H, Ruskin, JN & Reid, PR 1985, 'Flecainide: Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia', The American Journal of Cardiology, vol. 55, no. 8, pp. 956-962. https://doi.org/10.1016/0002-9149(85)90726-X
Platia, Edward V. ; Estes, N. A Mark ; Heine, Donald L. ; Griffith, Lawrence S C ; Garan, Hasan ; Ruskin, Jeremy N. ; Reid, Philip R. / Flecainide : Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. In: The American Journal of Cardiology. 1985 ; Vol. 55, No. 8. pp. 956-962.
@article{746f36502f2a494f8626623814089e73,
title = "Flecainide: Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia",
abstract = "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 ± 87 mg [mean ±standard deviation]). An average of 4 antiarrhythmic agents were used and were unsuccessful before therapy with flecainide was begun. During 64 ± 16 hours of control Holter monitoring in 16 patients, all had 1 or more salvos of VT, as well as ventricular premature complexes (VPCs). Programmed stimulation during the control period induced VT in 17 of 22 patients. After flecainide therapy, Holter monitoring showed elimination of all forms of VT in all but 1 patient, as well as significant reduction of paired VPCs by 95{\%} (p <0.03) and single VPCs by 70{\%} (p <0.005). Electrophysiologic study during flecainide therapy showed significant increases in AH, HV, PR, QRS and QTc intervals, and the ventricular effective refractory period. Programmed stimulation in 17 patients taking flecainide, with a mean plasma level of 1,075 ± 521 ng/ml, showed ablation of inducible VT in only 2 patients, a worsening in 5 and continued VT inducibility in 10. Adverse effects that required drug withdrawal were infrequent and encountered in patients who received higher drug levels: 1 patient with congestive heart failure and 1 with severe sinus bradycardia. Thus, although flecainide suppresses complex ventricular arrhythmias on Holter recordings, it rarely alters the response to programmed stimulation. Caution is recommended in its use for recurrent sustained VT or VF and in the interpretation of electrophysiologic studies until the predictive value of programmed stimulation with flecainide therapy is established.",
author = "Platia, {Edward V.} and Estes, {N. A Mark} and Heine, {Donald L.} and Griffith, {Lawrence S C} and Hasan Garan and Ruskin, {Jeremy N.} and Reid, {Philip R.}",
year = "1985",
month = "4",
day = "1",
doi = "10.1016/0002-9149(85)90726-X",
language = "English (US)",
volume = "55",
pages = "956--962",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Flecainide

T2 - Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia

AU - Platia, Edward V.

AU - Estes, N. A Mark

AU - Heine, Donald L.

AU - Griffith, Lawrence S C

AU - Garan, Hasan

AU - Ruskin, Jeremy N.

AU - Reid, Philip R.

PY - 1985/4/1

Y1 - 1985/4/1

N2 - Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 ± 87 mg [mean ±standard deviation]). An average of 4 antiarrhythmic agents were used and were unsuccessful before therapy with flecainide was begun. During 64 ± 16 hours of control Holter monitoring in 16 patients, all had 1 or more salvos of VT, as well as ventricular premature complexes (VPCs). Programmed stimulation during the control period induced VT in 17 of 22 patients. After flecainide therapy, Holter monitoring showed elimination of all forms of VT in all but 1 patient, as well as significant reduction of paired VPCs by 95% (p <0.03) and single VPCs by 70% (p <0.005). Electrophysiologic study during flecainide therapy showed significant increases in AH, HV, PR, QRS and QTc intervals, and the ventricular effective refractory period. Programmed stimulation in 17 patients taking flecainide, with a mean plasma level of 1,075 ± 521 ng/ml, showed ablation of inducible VT in only 2 patients, a worsening in 5 and continued VT inducibility in 10. Adverse effects that required drug withdrawal were infrequent and encountered in patients who received higher drug levels: 1 patient with congestive heart failure and 1 with severe sinus bradycardia. Thus, although flecainide suppresses complex ventricular arrhythmias on Holter recordings, it rarely alters the response to programmed stimulation. Caution is recommended in its use for recurrent sustained VT or VF and in the interpretation of electrophysiologic studies until the predictive value of programmed stimulation with flecainide therapy is established.

AB - Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 ± 87 mg [mean ±standard deviation]). An average of 4 antiarrhythmic agents were used and were unsuccessful before therapy with flecainide was begun. During 64 ± 16 hours of control Holter monitoring in 16 patients, all had 1 or more salvos of VT, as well as ventricular premature complexes (VPCs). Programmed stimulation during the control period induced VT in 17 of 22 patients. After flecainide therapy, Holter monitoring showed elimination of all forms of VT in all but 1 patient, as well as significant reduction of paired VPCs by 95% (p <0.03) and single VPCs by 70% (p <0.005). Electrophysiologic study during flecainide therapy showed significant increases in AH, HV, PR, QRS and QTc intervals, and the ventricular effective refractory period. Programmed stimulation in 17 patients taking flecainide, with a mean plasma level of 1,075 ± 521 ng/ml, showed ablation of inducible VT in only 2 patients, a worsening in 5 and continued VT inducibility in 10. Adverse effects that required drug withdrawal were infrequent and encountered in patients who received higher drug levels: 1 patient with congestive heart failure and 1 with severe sinus bradycardia. Thus, although flecainide suppresses complex ventricular arrhythmias on Holter recordings, it rarely alters the response to programmed stimulation. Caution is recommended in its use for recurrent sustained VT or VF and in the interpretation of electrophysiologic studies until the predictive value of programmed stimulation with flecainide therapy is established.

UR - http://www.scopus.com/inward/record.url?scp=0021827875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021827875&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(85)90726-X

DO - 10.1016/0002-9149(85)90726-X

M3 - Article

C2 - 3984883

AN - SCOPUS:0021827875

VL - 55

SP - 956

EP - 962

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -